Proportion participants that switched to another biologic due to loss of response ‐ not measured · people with rheumatoid arthritis with low disease activity using a standard dose of anti‐TNF agents
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Proportion of participants with minimal radiographic progression · people with rheumatoid arthritis with low disease activity using a standard dose of anti‐TNF agents
Anti‐TNF discontinuation leads to higher proportion participants with minimal radiographic progression compared with anti‐TNF continuation (high certainty).
1 finding from 1 review
Function · people with rheumatoid arthritis with low disease activity using a standard dose of anti‐TNF agents
1 finding from 1 review
Number of serious adverse events · people with rheumatoid arthritis with low disease activity using a standard dose of anti‐TNF agents
It is very uncertain whether anti‐TNF discontinuation changes number of serious adverse events compared with anti‐TNF continuation (very low certainty).
1 finding from 1 review
Withdrawals due to adverse events · people with rheumatoid arthritis with low disease activity using a standard dose of anti‐TNF agents
Anti‐TNF discontinuation showed no clear difference in withdrawals due to adverse events compared with anti‐TNF continuation (moderate certainty).
1 finding from 1 review
Disease activity · people with rheumatoid arthritis with low disease activity using a standard dose of anti‐TNF agents
1 finding from 1 review
Maintenance of clinical remission · people with rheumatoid arthritis with low disease activity using a standard dose of anti‐TNF agents
Anti‐TNF discontinuation may leads to lower proportion of participants with persistent remission compared with anti‐TNF continuation (low certainty).
1 finding from 1 review
Disease activity · people with rheumatoid arthritis with low disease activity using a standard dose of anti‐TNF agents
1 finding from 1 review
Maintenance of clinical remission · people with rheumatoid arthritis with low disease activity using a standard dose of anti‐TNF agents
Anti‐TNF dose reduction showed no clear difference in proportion of participants with persistent remission compared with anti‐TNF continuation (low certainty).
1 finding from 1 review
Proportion of participants switched to another biologic · people with rheumatoid arthritis with low disease activity using a standard dose of anti‐TNF agents
Anti‐TNF dose reduction may leads to lower proportion of participants switched to another biologic compared with anti‐TNF continuation (low certainty).
1 finding from 1 review
Proportion of participants with minimal radiographic progression · people with rheumatoid arthritis with low disease activity using a standard dose of anti‐TNF agents
Anti‐TNF dose reduction showed no clear difference in proportion of participants with minimal radiographic progression compared with anti‐TNF continuation (moderate certainty).
1 finding from 1 review
Function · people with rheumatoid arthritis with low disease activity using a standard dose of anti‐TNF agents
1 finding from 1 review
Number of serious adverse events · people with rheumatoid arthritis with low disease activity using a standard dose of anti‐TNF agents
Anti‐TNF dose reduction showed no clear difference in number of serious adverse events compared with anti‐TNF continuation (low certainty).
1 finding from 1 review
Withdrawals due to adverse events · people with rheumatoid arthritis with low disease activity using a standard dose of anti‐TNF agents
Anti‐TNF dose reduction showed no clear difference in withdrawals due to adverse events compared with anti‐TNF continuation (low certainty).
1 finding from 1 review
Disease activity · people with rheumatoid arthritis with low disease activity using a standard dose of anti‐TNF agents
1 finding from 1 review
Maintenance of clinical remission · people with rheumatoid arthritis with low disease activity using a standard dose of anti‐TNF agents
Anti‐TNF disease activity–guided dose tapering showed no clear difference in proportion of participants with persistent remission compared with anti‐TNF continuation (high certainty).
1 finding from 1 review
Proportion of participants switched to another biologic due to loss of response · people with rheumatoid arthritis with low disease activity using a standard dose of anti‐TNF agents
Anti‐TNF disease activity–guided dose tapering showed no clear difference in proportion of participants switched to another biologic due to loss… compared with anti‐TNF continuation (low certainty).
1 finding from 1 review
Proportion of participants with minimal radiographic progression · people with rheumatoid arthritis with low disease activity using a standard dose of anti‐TNF agents
Anti‐TNF disease activity–guided dose tapering showed no clear difference in proportion of participants with minimal radiographic progression compared with anti‐TNF continuation (low certainty).
1 finding from 1 review
Function · people with rheumatoid arthritis with low disease activity using a standard dose of anti‐TNF agents
1 finding from 1 review
Number of serious adverse events · people with rheumatoid arthritis with low disease activity using a standard dose of anti‐TNF agents
It is very uncertain whether anti‐TNF disease activity–guided dose tapering changes number of serious adverse events compared with anti‐TNF continuation (very low certainty).
1 finding from 1 review